Haleon PLC Sponsored ADR (NYSE:HLN) Given Average Rating of “Moderate Buy” by Brokerages

Haleon PLC Sponsored ADR (NYSE:HLN) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, four have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $12.3250.

A number of research firms recently issued reports on HLN. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft downgraded Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Finally, HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st.

Haleon Stock Performance

HLN opened at $9.95 on Monday. The business’s 50-day moving average price is $10.50 and its two-hundred day moving average price is $9.89. Haleon has a 1 year low of $8.71 and a 1 year high of $11.42. The company has a market capitalization of $44.28 billion, a price-to-earnings ratio of 25.50 and a beta of 0.26. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71.

Haleon Announces Dividend

The firm also recently declared a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be paid a $0.1307 dividend. This represents a yield of 251.0%. The ex-dividend date is Friday, April 10th. Haleon’s payout ratio is presently 28.21%.

Hedge Funds Weigh In On Haleon

A number of large investors have recently modified their holdings of the business. Morgan Stanley increased its position in shares of Haleon by 16.0% in the fourth quarter. Morgan Stanley now owns 21,495,383 shares of the company’s stock valued at $217,318,000 after acquiring an additional 2,962,856 shares during the last quarter. Norges Bank acquired a new position in Haleon during the fourth quarter valued at approximately $163,529,000. Bank of America Corp DE grew its stake in Haleon by 116.7% in the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Haleon by 36.6% in the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after purchasing an additional 3,207,986 shares in the last quarter. Finally, Sculptor Capital LP grew its stake in Haleon by 5.1% in the fourth quarter. Sculptor Capital LP now owns 10,454,868 shares of the company’s stock valued at $105,699,000 after purchasing an additional 505,000 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.